
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Edwards Lifesciences Corp (EW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $87.52
1 Year Target Price $87.52
10 | Strong Buy |
4 | Buy |
17 | Hold |
0 | Sell |
1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.48% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 45.95B USD | Price to earnings Ratio 32.74 | 1Y Target Price 87.52 |
Price to earnings Ratio 32.74 | 1Y Target Price 87.52 | ||
Volume (30-day avg) 32 | Beta 1.08 | 52 Weeks Range 64.01 - 83.00 | Updated Date 08/15/2025 |
52 Weeks Range 64.01 - 83.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-22 | When Before Market | Estimate 0.6231 | Actual 0.67 |
Profitability
Profit Margin 72.96% | Operating Margin (TTM) 28.12% |
Management Effectiveness
Return on Assets (TTM) 8.42% | Return on Equity (TTM) 15.53% |
Valuation
Trailing PE 32.74 | Forward PE 31.55 | Enterprise Value 42539878000 | Price to Sales(TTM) 8.08 |
Enterprise Value 42539878000 | Price to Sales(TTM) 8.08 | ||
Enterprise Value to Revenue 7.48 | Enterprise Value to EBITDA 23.27 | Shares Outstanding 587100032 | Shares Floating 581046999 |
Shares Outstanding 587100032 | Shares Floating 581046999 | ||
Percent Insiders 0.91 | Percent Institutions 88.28 |
Upturn AI SWOT
Edwards Lifesciences Corp

Company Overview
History and Background
Edwards Lifesciences was founded in 1958 by Miles "Lowell" Edwards and Albert Starr. Initially focused on heart valve replacement, it pioneered the first commercially available artificial heart valve. The company has evolved into a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
Core Business Areas
- Transcatheter Aortic Valve Replacement (TAVR): This segment focuses on minimally invasive heart valve replacement through a catheter, primarily for aortic stenosis. It's their largest revenue driver.
- Surgical Structural Heart: This segment offers surgical heart valve repair and replacement products, including tissue and mechanical valves, as well as annuloplasty rings and other surgical structural heart therapies.
- Critical Care: This segment provides hemodynamic monitoring systems used in intensive care units to measure a patient's cardiac function and fluid status.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): This is an emerging segment focused on developing minimally invasive solutions for mitral and tricuspid valve diseases.
Leadership and Structure
Edwards Lifesciences is led by CEO Bernard Zovighian. The company has a traditional corporate structure with functional departments like R&D, Sales, Marketing, Operations, and Finance. It also has regional teams focused on specific geographic markets.
Top Products and Market Share
Key Offerings
- SAPIEN TAVR Valves: Edwards' SAPIEN family of TAVR valves are the market leader in the transcatheter aortic valve replacement space. Estimated market share is around 50%. Competitors include Medtronic (MDT) and Boston Scientific (BSX). High margin product line and a major revenue generator.
- Inspiris Resilia Aortic Valve: This surgical aortic valve is designed for durability and provides patients with potentially longer-lasting valve replacement options. Competitors include Medtronic (MDT) and Abbott (ABT).
- Swan-Ganz Catheters: These catheters are used for advanced hemodynamic monitoring in critically ill patients. They provide real-time data on cardiac output and other vital parameters. Main competitor is ICU Medical (ICUI).
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and demographic shifts (aging population). The structural heart market is growing rapidly due to the increasing prevalence of heart valve disease and the preference for minimally invasive procedures.
Positioning
Edwards Lifesciences is a leader in the structural heart disease market, particularly in TAVR. Its competitive advantages include its strong brand reputation, extensive clinical data supporting its products, and robust R&D pipeline.
Total Addressable Market (TAM)
The global structural heart market is estimated to be worth over $20 billion. Edwards is well-positioned to capture a significant portion of this market due to its leadership in TAVR and expanding portfolio in TMTT.
Upturn SWOT Analysis
Strengths
- Market leader in TAVR
- Strong brand reputation
- Extensive clinical data
- Robust R&D pipeline
- Global presence
Weaknesses
- High reliance on TAVR market
- Relatively higher price points compared to competitors
- Potential for increased competition
- Exposure to regulatory changes
Opportunities
- Expansion into emerging markets
- Growth in TMTT market
- Development of new technologies and therapies
- Partnerships and acquisitions
Threats
- Increased competition from existing and new players
- Pricing pressures from healthcare providers and payers
- Adverse regulatory changes
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
- SYK
Competitive Landscape
Edwards has a strong lead in TAVR with SAPIEN valves, known for robust clinical data and ease of use. Medtronic poses a significant threat with its Evolut platform. Boston Scientific and Abbott are also competing for market share, creating pricing pressures.
Major Acquisitions
Harpoon Medical
- Year: 2017
- Acquisition Price (USD millions): 250
- Strategic Rationale: Harpoon Medicalu2019s investigational device for minimally invasive surgical repair of the mitral valve was acquired to expand Edward's portfolio of mitral valve therapies.
Growth Trajectory and Initiatives
Historical Growth: Edwards Lifesciences has experienced strong revenue growth in recent years, primarily driven by the adoption of TAVR technology. Their growth is expected to continue but at a slightly lower rate.
Future Projections: Analysts project continued growth for Edwards Lifesciences, driven by TAVR, TMTT and the overall increase in cardiovascular disease as the population ages.
Recent Initiatives: Recent initiatives include expanding the indications for TAVR, investing in TMTT research and development, and expanding its presence in emerging markets.
Summary
Edwards Lifesciences is a strong company with a dominant position in the growing TAVR market. Its robust R&D pipeline and investments in TMTT position it well for future growth. However, increasing competition and pricing pressures remain key challenges. Continued innovation and expansion into new markets will be crucial for sustaining its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- SEC Filings (10K, 10Q)
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.